183 related articles for article (PubMed ID: 34297312)
1. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
Bonifacio M; Maheshwari V; Tran D; Agostoni G; Filioussi K; Viana R
Pharmacoecon Open; 2022 Jan; 6(1):95-104. PubMed ID: 34297312
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
[TBL] [Abstract][Full Text] [Related]
13. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
[No Abstract] [Full Text] [Related]
15. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.
Conti RM; Padula WV; Becker RV; Salamone S
J Manag Care Spec Pharm; 2021 Aug; 27(8):1077-1085. PubMed ID: 34337991
[No Abstract] [Full Text] [Related]
16. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.
Rochau U; Kluibenschaedl M; Stenehjem D; Kuan-Ling K; Radich J; Oderda G; Brixner D; Siebert U
Leuk Res Treatment; 2015; 2015():982395. PubMed ID: 26783469
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
[TBL] [Abstract][Full Text] [Related]
18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]